125678-52-6

Basic information

• Product Name: Diethylaminopropyne formate
• Synonyms: diethylaminopropyne formate;3-N,N-Diethylamino-1-propyne formate;Diethylamino-2-propyne, sulfate;PABS;DIETHYLAMINOPROPYNE FORMIC ACID;DiethylaMinopropyne forMate (PABS);PABS(DiethylaMinopropyne forMate)
• CAS NO: 125678-52-6
• Molecular Formula: C8H15NO2
• Molecular Weight: 157.21
• Mol File: 125678-52-6.mol

Chemical Properties

• Appearance: /
• Density: 1.04
• Refractive Index: 1.4190-1.4320
• CAS DataBase Reference: Diethylaminopropyne formate(CAS DataBase Reference)
• NIST Chemistry Reference: Diethylaminopropyne formate(125678-52-6)
• EPA Substance Registry System: Diethylaminopropyne formate(125678-52-6)

Safety Data

• Hazardous Substances Data: 125678-52-6(Hazardous Substances Data)

Usage

Uses

Used in Electroplating Industry:
Diethylaminopropyne formate is used as an intermediate of electroplating additive for the preparation of nickel plating brightening agents. Its incorporation into the electroplating process enhances the brightness and quality of the nickel plating, making it an essential component in the production of high-quality plated surfaces.

InChI:InChI=1/C7H13N.CH2O2/c1-4-7-8(5-2)6-3;2-1-3/h5-6H2,1-3H3;1H,(H,2,3)

Upstream product

• 13249-59-7 diethyl-(2-bromo-allyl)-amine 
• 19764-53-5 6-diethylamino-3-methyl-hex-4-yn-3-ol 
• 124-41-4 sodium methylate 
• 624-65-7 2-propynyl chloride 
• 109-89-7 diethylamine 
• 50-00-0 formaldehyd 
• 124-40-3 dimethyl amine 
• 74-86-2 acetylene 
• 106-96-7 propargyl bromide 
• 10575-25-4 4-diethylamino-2-butyn-1-ol 
• 736135-10-7 diethyl-(3,3-dichloro-allyl)-amine 
• 32493-43-9 C₇H₁₃N*CClNO₃S 
• 110-91-8 morpholine 
• 6165-76-0 propargyl p-toluenesulfonate 

Downstream Products

• 19689-20-4 N,N-diethylhept-2-yn-1-amine 
• 73117-10-9 N,N-diethyl-2-butin-1-ylamine 
• 66894-62-0 diethyl-oct-2-ynyl-amine 
• 102465-67-8 1-cyclohexyl-4-diethylamino-1-phenyl-but-2-yn-1-ol 
• 500298-50-0 diethyl-hex-2-ynyl-amine 
• 6323-82-6 but-2-ynyldiethylamine 
• 614-51-7 4-(diethylamino)-1-phenylbut-2-yn-1-ol 
• 82511-16-8 6-(3-Diethylamino-prop-1-ynyl)-6-hydroxy-3,4-dimethoxy-cyclohexa-2,4-dienone 
• 95925-74-9 (2-Cyclohexyl-allyl)-diethyl-amine 
• 95925-71-6 ((Z)-3-Cyclohexyl-allyl)-diethyl-amine 
• 78167-36-9 7-(N,N-Diaethylamino)-4-methyl-1,1,1-triphenyl-5-heptin-2-on 
• 121194-55-6 N,N-Diethyl-N'-phenyl-but-2-yne-1,4-diamine 
• 121194-56-7 N,N-Diethyl-N'-m-tolyl-but-2-yne-1,4-diamine 
• 5424-68-0 2,5-bis((diethylamino)methyl)benzene-1,4-diol 

Relevant articles and documents

Assembly of Functionalized 4-Alkynylisoxazoles by Palladium-Catalyzed Three-Component Cascade Cyclization/Alkynylation

A novel N-heterocyclic carbene (NHC)-palladium-catalyzed three-component cascade cyclization/alkynylation for the synthesis of structurally diverse 4-alkynylisoxazoles was efficiently developed in ionic liquids. The operational simplicity, without additives, no additional ligands, and 0.5 mol % catalyst loading under air are some of the attractive features of this present protocol.

Design, synthesis,: In silico docking studies and biological evaluation of novel quinoxaline-hydrazide hydrazone-1,2,3-triazole hybrids as α-glucosidase inhibitors and antioxidants

A new series of quinoxaline-hydrazidehydrazone-1,2,3-triazole hybrids, 14a-j, 15a-j and 16a-e, was designed, synthesized and screened for in vitro α-glucosidase and antioxidant activities. For the synthesis of the target compounds, quinoxaline hydrazides were condensed with benzaldehyde triazoles in the presence of AcOH (cat) in ethanol. The key step in the preparation of compounds 8a-j was the Cu(i)-catalyzed [3+2] cycloaddition reaction (CuAAC) with appropriate alkynes (6, 7) and azides, and 13a-j were prepared from simple aldehydes utilizing the same click reaction as the final step. Quinoxaline hydrazides (3, 3a) were synthesized from o-phenylenediamine and pyruvic acid via three-step reactions comprising cyclization, alkylation and hydrazidation. Among these hybrids, 14a (IC50 = 21.92 μg mL-1), 14b (IC50 = 22.32 μg mL-1), 14c (IC50 = 23.58 μg mL-1) and 15a (IC50 = 24.50 μg mL-1) showed good α-glucosidase inhibition compared with the standard acarbose (IC50 = 22.32 μg mL-1). Further, the scavenging abilities of the synthesized compounds as antioxidants were studied using the DPPH, H2O2, and NO methods; as per the obtained results, compounds 14a, 14b, 14c and 15a displayed good antioxidant activity. Docking studies of the active compounds and acarbose as a standard with α-glucosidase (PDB ID: 2ZEO) were performed to determine the molecular interactions between the inhibitors and the active site of the enzyme. Better binding energies of the active compounds than of the standard acarbose were observed. Therefore, our new hybrid molecules may be useful for further optimization in developing new lead molecules with both α-glucosidase inhibition and antioxidant activities.

Synthesis, surface properties and bioactivity of novel 4-Substituted 1,2,3-Triazole quaternary ammonium surfactants

Series of novel 1,2,3-triazole based quaternary ammonium surfactants with different hydrophobic chain length and head group substituents were synthetized and characterized. Their surface properties and aggregation behavior were discussed on the basis of tensiometry and conductimetry measurements by using several parameters, including critical micelle concentration (CMC), surface tension at the cmc (γcmc), adsorption efficiency (pC20), effectiveness of surface tension reduction (Πcmc), minimum surface area occupied by a molecule (Amin) at the air ? water interface and standard Gibbs free energy of micellization ΔGMic0. These heterocyclic surfactants exhibit much lower CMC values as compared with those reported for conventional alkyltriethyl ammoniums and alkylbenzyldiethyl ammonium salts. Their micelles formation and surface adsorption in aqueous media can be tuned out through a suitable choice of the substituent attached to the polar head. Triethyl ammonium (CnTzTEA] and diethylbenzyl ammonium surfactants (CnTzBz) showed improved micellization behavior than tetradecyl diethyl ammonium (CnTzC14) homologous. The in vitro antimicrobial activity of the surfactants against B. subtilis, P. aerugenosa and A.niger strains was also investigated. CnTzBz series possessing benzyl chain showed better activity against all the tested microorganisms with minimum inhibitory concentration ranging from 6 to 57 μmol/L.

Pleuromutilin derivative with triazole side chain, and preparation method and application thereof

The invention relates to the technical field of medicinal chemistry, in particular to a pleuromutilin derivative with a triazole side chain, and a preparation method and application thereof. The pleuromutilin derivative disclosed by the invention has the triazole side chain and a pleuromutilin parent nucleus structure; and in-vitro experiment results and animal experiment results show that the pleuromutilin derivative disclosed by the invention has good antibacterial activity on Staphylococcus aureus, and is particularly applicable as a novel antibacterial drug for systemic infections of animals or human beings.

Design, synthesis and biological activities of novel pleuromutilin derivatives with a substituted triazole moiety as potent antibacterial agents

A series of novel pleuromutilin derivatives possessing 1,2,3-triazole moieties were synthesized via click reactions under mild conditions. The in vitro antibacterial activities of these derivatives against 4 strains of S. aureus (MRSA ATCC 43300, ATCC 29213, AD 3, and 144) and 1 strain of E. coli (ATCC 25922) were tested by the broth dilution method. The majority of the synthesized derivatives displayed potent antibacterial activities against MRSA (MIC = 0.125–2 μg/mL). It was also found that most compounds had no significant inhibitory effect on the proliferation of RAW264.7 cells at the concentration of 8 μg/mL. Among these derivatives, compound 32 (～1.71 log10 CFU/g) containing dimethylamine group side chain displayed more effective than tiamulin (～0.77 log10 CFU/g) at the dose of 20 mg/kg in reducing MRSA load in thigh infected mice. Additionally, compound 32 (the survival rate was 50%) also displayed superior in vivo efficacy to that of tiamulin (the survival rate was 20%) in the mouse systemic model. Structure-activity relationship (SAR) studies resulted in compound 32 with the most potent in vitro and in vivo antibacterial activity among the series. Moreover, compound 32 was evaluated in CYP450 inhibition assay and showed moderate in vitro inhibition of CYP3A4 (IC50 = 6.148 μM).

Design, synthesis and biological evaluation of novel pleuromutilin derivatives containing piperazine and 1,2,3-triazole linker

A series of novel pleuromutilin derivatives containing piperazine ring, 1, 2, 3-triazoles and secondary amines on the side chain of C14 were synthesized under mild conditions via click reaction. The in vitro antibacterial activities of the synthesized derivatives against four strains of Staphylococcus aureus (MRSA ATCC 43300, ATCC 29213, 144 and AD3) and one strain of Escherichia coli (ATCC 25922) were evaluated by the broth dilution method. Among these derivatives, 22–[2-(4-((4-nitrophenyl piperazine)methyl)-1,2,3-triazol-1-yl)-1-(piperazine-1-yl) ethyl-1-one] deoxy pleuromutilin (compound 59) showed the most prominent in vitro antibacterial effect against MRSA (MIC = 1 μg/mL). Furthermore, compound 59 displayed more rapid bactericidal kinetic than tiamulin time-kill studies and possessed a longer PAE than tiamulin against MRSA in vitro. In addition, in vivo antibacterial activities of compound 59 against MRSA were further evaluated employing thigh infection model. And compound 59 (-8.89 log10 CFU/mL) displayed superior activities than tiamulin. Compound 59 was further evaluated in CYP450 inhibition assay and the results showed that it exhibited low to moderate inhibitory effects on CYP1A2, CYP2E1, CYP2D6 and CYP3A4 enzymes. The PK properties of compound 59 were then measured. The half-life (t1/2), clearance rate (Cl) and the area under the plasma concentration time curve (AUC0→∞) of compound 59 were 0.74 h, 0.29 L/h/kg and 46.28 μg·h/mL, respectively.

Pleuromutilin derivative with 2-aminothiophenol and 1,2,3-triazole side chain, preparation and application

The invention belongs to the field of medicinal chemistry, and particularly relates to a pleuromutilin derivative with 2-aminothiophenol and a 1,2,3-triazole side chain, preparation and application. The pleuromutilin derivative with 2-aminothiophenol and the 1,2,3-triazole side chain is a compound of a formula 2 or a pharmaceutically acceptable salt of the compound, and a solvent compound, an enantiomer, a diastereomer and a tautomer of the compound of the formula 2 or the pharmaceutically acceptable salt of the compound or a mixture of the compound of the formula 2 or the pharmaceutically acceptable salt of the compound in any ratio, and includes a racemic mixture, and the compound has good inhibition to methicillin-resistant staphylococcus aureus activity, and is especially suitable forbeing used as a novel antibacterial drug for prevention and treatment of infectious diseases caused by human or animals or methicillin-resistant staphylococcus aureus or multi-drug resistant bacteria.(Please see the specification for the formula).

Pleuromutilin derivative containing piperazine and 1, 2, 3-triazole secondary amine side chains, and preparation and applications thereof

The invention belongs to the field of pharmaceutical chemistry, and especially relates to a pleuromutilin derivative containing piperazine and 1, 2, 3-triazole secondary amine side chains, and preparation and applications thereof. The pleuromutilin derivative containing piperazine and 1, 2, 3-triazole secondary amine side chains is a compound represented by formula 2 or a pharmaceutically acceptable salt of the compound, or a solvate, an enantiomer, a diastereomer, a tautomer of the compound represented by formula 2 or the pharmaceutically acceptable salt of the compound, or a mixture of the above substances at a random ratio comprising a racemic mixture. The compound possesses excellent in vitro antibacterial activity, the cost is lower than that of valnemulin and retapamulin, so that thecompound is especially suitable to be taken as a novel antibacterial drug in prevention and treatment of human or animal bacterial infectious diseases, especially infectious diseases caused by medicine resistant Staphylococcus aureus.

TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

The present disclosure relates to a novel tetrahydropyridine derivative compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, methods for preparing the compounds, methods for inhibiting UDP-3-O—(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC), methods for treating Gram-negative bacterial infections, the use of the compounds for the preparation of therapeutic medicaments for treating Gram-negative bacterial infections, and pharmaceutical compositions for prevention or treatment of Gram-negative bacterial infections, which contain the compounds. The compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure can exhibit excellent effects on the treatment bacterial infections.

Supported copper (I) catalyst from fish bone waste: An efficient, green and reusable catalyst for the click reaction toward N-substituted 1,2,3-TRIAZOLES

An eco-efficient, green, and multi-gram procedure is presented for one-pot multicomponent synthesis of N-substituted 1,2,3-triazoles by using waste fishbone powders supported CuBr (FBPs-CuBr) as catalyst. FBPs-CuBr is found to be an efficient heterogeneous catalyst and a series of 1,2,3-triazoles are obtained in moderate to excellent yields in water under MW irradiation (70–98%). It can be separated conveniently by a simple filtration and reused at least seven consecutive runs with a slight drop in the product yields. Furthermore, the desired product still could be obtained in 80% yield when the scale of the reaction was increased to 40.0 mmol.